Feature | September 03, 2014 | Raissa Rocha

IMRT, IGRT Continues to Grow in Use Among Arc-based Radiotherapies

This article appeared as an introduction to a Comparison Chart on Arc-based Radiotherapy Systems in the September 2014 issue.

Arc-based radiation therapy continues to gain ground as physicians opt for treatment options that not only are more precisely tailored to each tumor site, but also delivered in fewer visits, which is significantly more convenient for both patients and cancer centers. With a variety of radiation therapy techniques available, from intensity-modulated radiation therapy (IMRT) and whole-body irradiation (WBI) to proton therapy and stereotactic body radiation therapy (SBRT), cancer centers around the country are now, more than ever, able to offer patients a more effective solution for targeting and treating their diseases.

Types of Techniques

Recent advances are allowing radiation oncologists to use arc-based therapies to target a wide range of cancers, including prostate, breast, and head and neck. Not all solutions will work for all cancers, nor will all patients be suitable for all solutions, but each will typically deliver high radiation doses to the tumor site while minimizing damage to surrounding healthy tissue.

The reasons for radiation therapy can vary. Adjuvant radiotherapies target surgical sites to sterilize residual cancer; for example, an oncologist may use radiation therapy on lumpectomy cavities to treat any remaining cancer cells in the breast. Arc-based radiotherapy can also be used prior to operations, sterilizing areas around the tumor site to improve surgical outcomes. Radiotherapy may also be used to alleviate symptoms associated with tumors or to eliminate cancer cells entirely if possible.

The increasing use of multileaf collimators (MLC) has led to oncologists delivering higher energy X-rays deeper under the skin to more accurately penetrate tumors. In an MLC, each leaf is adjusted independently to block any part of the radiation field, allowing for beams to conform to the shape of the tumor and avoid healthy tissue. The latest MLCs typically have up to 160 leaves; Elekta’s Agility system is one example of intelligent beam-shaping technology. Siemens Healthcare also offers a 160-leaf MLC in several of its linear accelerators.

IMRT is one radiotherapy treatment that has been growing quickly in adoption and is considered to be standard in some cases. The technique actively modulates radiation beams around the patient during delivery, changing not only in direction but in intensity as well. One form of IMRT, Accuray’s TomoTherapy system, uses computed tomography (CT) imaging to ensure patients are correctly aligned on the day of their customized treatments. TomoTherapy was recently cited by MD Buyline in its Q2 2014 Market Intelligence Briefing as having the highest composite overall user satisfaction rating among radiation treatment delivery systems, along with the CyberKnife robotic radiosurgery system, also by Accuray.

Another form of radiotherapy, volumetric-modulated arc therapy (VMAT), expands on the concept by offering arc-based radiation that is continuous and uninterrupted, rather than in a stop-and-go procedure in which patients receive external radiation from a set number of orientations, or slices. Elekta’s Versa HD system offers VMAT capabilities with high-definition, high-speed beam shaping over a 40- by 40-cm field; it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2013. Institutions that have installed the Versa HD since then include HM Hospitales in Spain, Johns Hopkins Hospital in Baltimore and Swedish Medical Center in Seattle.

Similarly, Varian Medical Systems’ RapidArc technology delivers sculpted 3-D dose distribution with a single 360-degree rotation of the gantry. Treatment time is faster than IMRT, but requires a similar procedure, allowing for easier implementation. Varian offers RapidArc on all new Trilogy delivery systems and Clinac iX linear accelerators.

Radiotherapy Advancements

There are many add-ons and enhancements available for cancer centers looking to improve their arc-based radiotherapy arsenal. The use of real-time image guidance (also known as image-guided radiation therapy, or IGRT) allows physicians to more precisely localize and target tumors within the body without compromising healthy tissues. IGRT may involve the use of CT datasets or matching radiographs in order to determine coordinates.

Another imaging modality, magnetic resonance imaging (MRI), is under consideration for future use in radiotherapy image guidance. ViewRay Inc. showcased its MRIdian system, an MRI-guided radiation therapy system, at the 2014 annual meeting of the American Association of Physicists in Medicine (AAPM) in July. Dubbed the world’s first and only such system, the MRIdian is designed to improve cancer treatments with continuous soft tissue imaging, allowing clinicians to localize the cancer and monitor where radiation doses are being delivered.

Elekta and Philips Healthcare’s research consortium to develop an MRI-guided radiotherapy system reached seven members in August, with the addition of The Christie NHS Foundation Trust, a Manchester, England-based cancer center. Other members of the consortium include the University Medical Center Utrecht, the Netherlands; the University of Texas MD Anderson Cancer Center, Houston; and the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, among others.

The number of arc-based radiotherapy options in the market continues to grow with each new advancement that promises to deliver more precise radiation doses to more localized tumor sites, improving cures and quality of life for patients. With many vendors offering solutions, cancer centers looking to improve their programs with high-quality technologies should seek systems that best fit their needs.

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Varian Receives FDA 510k Clearance for Halcyon Treatment System
Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017
Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system,...
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Overlay Init